Cogent Biosciences (COGT) Current Assets (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Current Assets data on file, last reported at $877.8 million in Q1 2026.

• On a quarterly basis, Current Assets rose 247.12% year-over-year to $877.8 million in Q1 2026; TTM through Mar 2026 was $877.8 million, a 247.12% increase from a year earlier, with the FY2025 full-year figure at $910.4 million, up 207.06% from the prior year.
• Current Assets for Q1 2026 stood at $877.8 million, down from $910.4 million in the prior quarter.
• Over the last five years, Current Assets for COGT reached as high as $910.4 million in Q4 2025 and fell as low as $194.7 million in Q1 2022.
• Historically, Current Assets has averaged $372.8 million across 5 years, with a median of $296.5 million in 2024.
• Across the five-year window, Current Assets tumbled 42.77% in 2025 and soared 247.12% in 2026, its largest moves.
• Year by year, Current Assets stood at $265.0 million in 2022, then gained by 2.19% to $270.8 million in 2023, then grew by 9.49% to $296.5 million in 2024, then surged by 207.06% to $910.4 million in 2025, then declined by 3.58% to $877.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $877.8 million in Q1 2026, $910.4 million in Q4 2025, and $397.2 million in Q3 2025.